Rice Midstream Partners LP (RMP) Forms $17.02 Double Bottom; Avenue Therapeutics (ATXI) Shorts Lowered By 6.45%

Rice Midstream Partners LP (RMP) formed double bottom with $15.49 target or 9.00% below today’s $17.02 share price. Rice Midstream Partners LP (RMP) has $1.74B valuation. The stock decreased 0.58% or $0.1 during the last trading session, reaching $17.02. About 490,477 shares traded. Rice Midstream Partners LP (NYSE:RMP) has declined 26.32% since June 30, 2017 and is downtrending. It has underperformed by 38.89% the S&P500. Some Historical RMP News: 22/05/2018 – EQT Corp.: EQT Midstream Completes Drop-Down Transaction With Rice Midstream; 04/04/2018 – 4 Day Course: PMI-RMP Certification Training (June 12th-15th, 2018) – ResearchAndMarkets.com; 26/04/2018 – RICE MIDSTREAM PARTNERS LP – EACH HOLDER OF COMMON UNIT OF RMP WILL RECEIVE 0.3319 UNITS OF EQM, REPRESENTING EQUITY VALUE OF $2.1 BLN; 26/04/2018 – Merger of EQM and Rice Midstream Implies Transaction Value of $2.4B, Including Assumption of RMP Deb; 26/04/2018 – RICE MIDSTREAM PARTNERS LP – EQM WILL ALSO ASSUME RMP DEBT, WHICH TOTALED $325 MLN AS OF MARCH 31, 2018; 26/04/2018 – RICE MIDSTREAM PARTNERS LP – EQM HAS ENTERED INTO A $2.5 BLN 364-DAY SYNDICATED TERM LOAN FACILITY; 26/04/2018 – Rice Midstream Partners Agrees Not to Solicit Competing Acquisition Proposals, Enter Discussion; 15/03/2018 – EQT CORP – SCHLOTTERBECK HAS ALSO RESIGNED FROM CO’S BOARD; 26/04/2018 – EQT Midstream Partners, EQT GP Holdings, and Rice Midstream Partners Announce Streamlining Transaction; 15/03/2018 – EQT: Jerry Ashcroft Named President, CEO of EQT GP, EQT Midstream, Rice Midstream

Avenue Therapeutics Inc (NASDAQ:ATXI) had a decrease of 6.45% in short interest. ATXI’s SI was 5,800 shares in June as released by FINRA. Its down 6.45% from 6,200 shares previously. With 21,600 avg volume, 0 days are for Avenue Therapeutics Inc (NASDAQ:ATXI)’s short sellers to cover ATXI’s short positions. The SI to Avenue Therapeutics Inc’s float is 0.09%. The stock decreased 3.24% or $0.12 during the last trading session, reaching $3.58. About 13,089 shares traded. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has 0.00% since June 30, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical ATXI News: 21/05/2018 – AVENUE THERAPEUTICS INC – IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS; 03/05/2018 – AVENUE THERAPEUTICS INC – AS OF MARCH 31, 2018, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $15.0 MLN; 21/05/2018 – AVENUE THERAPEUTICS – ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019; 28/03/2018 Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol; 21/05/2018 – Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain; 21/05/2018 – ATXI SAYS INTRAVENOUS TRAMADOL ACHIEVED PRIMARY ENDPOINTS; 21/05/2018 – AVENUE THERAPEUTICS INC – IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL; 21/05/2018 – Another cheap, old drug is being freshened up for brand pricing in the US $ATXI; 21/05/2018 – AVENUE THERAPEUTICS INC – IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE

Among 4 analysts covering Rice Midstream Partners (NYSE:RMP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Rice Midstream Partners had 5 analyst reports since January 11, 2018 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Monday, February 12. BMO Capital Markets maintained Rice Midstream Partners LP (NYSE:RMP) rating on Thursday, January 11. BMO Capital Markets has “Buy” rating and $22.0 target. RBC Capital Markets maintained Rice Midstream Partners LP (NYSE:RMP) rating on Tuesday, January 16. RBC Capital Markets has “Hold” rating and $24.0 target. The stock of Rice Midstream Partners LP (NYSE:RMP) has “Hold” rating given on Monday, January 22 by Citigroup. The firm has “Market Perform” rating by Wells Fargo given on Thursday, February 22.

Analysts await Rice Midstream Partners LP (NYSE:RMP) to report earnings on August, 1. They expect $0.44 earnings per share, up 4.76% or $0.02 from last year’s $0.42 per share. RMP’s profit will be $45.01 million for 9.67 P/E if the $0.44 EPS becomes a reality. After $0.48 actual earnings per share reported by Rice Midstream Partners LP for the previous quarter, Wall Street now forecasts -8.33% negative EPS growth.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $37.78 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

Rice Midstream Partners LP (NYSE:RMP) Ratings Chart